Public Drug Program Formulary Tables – Psoriasis and Psoriatic Arthritis

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic Arthritis
British ColumbiaBiologics and BiosimilarsetanerceptEnbrel®No – S/A requests for psoriasis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis.  No – S/A requests for psoriatic arthritis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis.  
AlbertaBiologics and BiosimilarsEtanerceptEnbrel®Yes – S/A. Note: all requests for etanercept for patients weighing 63 kg or more will be assessed for
coverage with an etanercept biosimilar. Enbrel will be approved for new etanercept starts for pediatric patients weighing less than 63 kg.		No 
SaskatchewanBiologics and BiosimilarsEtanerceptEnbrel®Yes – EDS. New psoriasis and psoriatic arthritis patients (i.e., patients without previous EDS approval for Enbrel) will be eligible only for a listed biosimilar formulation Yes – EDS. New psoriasis and psoriatic arthritis patients (i.e., patients without previous EDS approval for Enbrel) will be eligible only for a listed biosimilar formulation 
ManitobaBiologics and BiosimilarsEtanerceptEnbrel®Yes – EDS. Erelzi or Brenzys will be the preferred etanercept option for all etanercept-naïve patients prescribed an etanercept product for psoriasis.Yes – EDS. Erelzi or Brenzys will be the preferred etanercept option for all etanercept-naïve patients prescribed an etanercept product for psoriatic arthritis.
OntarioBiologics and BiosimilarsEtanerceptEnbrel®Yes – L/UNo 
QuebecBiologics and BiosimilarsEtanerceptEnbrel®Yes – S/A. If treatment began before August 19, 2020 Yes – S/A. If treatment began before August 19, 2020 
New BrunswickBiologics and BiosimilarsEtanerceptEnbrel®No All new S/A requests will be approved for biosimilar versions only. Patients on Enbrel must switch to the biosimilar version by November 30, 2021.No. All new S/A requests will be approved for biosimilar versions only. Patients on Enbrel must switch to the biosimilar version by November 30, 2021.
Nova ScotiaBiologics and BiosimilarsEtanerceptEnbrel®Yes – EDS; for etanercept-naïve patients whose etanercept therapy is initiated after Nov 1, 2017, a biosimilar will be the product that is approved.  Yes – EDS; for etanercept-naïve patients whose etanercept therapy is initiated after Nov 1, 2017, a biosimilar will be the product that is approved.  
Prince Edward IslandBiologics and BiosimilarsEtanerceptEnbrel®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsEtanerceptEnbrel®Yes – S/A. All new S/A requests for coverage of etanercept received after September 9, 2020, will be approved for the biosimilar version only. Yes –S/A. All new S/A requests for coverage of etanercept received after September 9, 2020, will be approved for the biosimilar version only. 
NunavutBiologics and BiosimilarsEtanerceptEnbrel®NoYes – L/U
Northwest TerritoriesBiologics and BiosimilarsEtanerceptEnbrel®NoYes – L/U
YukonBiologics and BiosimilarsEtanerceptEnbrel®Yes - EDS ; all new etanercept patients will be covered for Brenzys or ErelziYes – EDS; all new etanercept patients will be covered for Erelzi 
NIHBBiologics and BiosimilarsEtanerceptEnbrel®NoYes- Only for clients who received approval for Enbrel before October 2, 2017
British ColumbiaBiologics and BiosimilarsEtanerceptErelzi™Yes - S/AYes – S/A
AlbertaBiologics and BiosimilarsEtanerceptErelzi™Yes – S/A Yes – S/A
SaskatchewanBiologics and BiosimilarsEtanerceptErelzi™Yes – EDS Yes – EDS
ManitobaBiologics and BiosimilarsEtanerceptErelzi™Yes – EDS  Yes – EDS
OntarioBiologics and BiosimilarsEtanerceptErelzi™Yes – L/U Yes – L/U
QuebecBiologics and BiosimilarsEtanerceptErelzi™Yes – S/AYes – S/A 
New BrunswickBiologics and BiosimilarsEtanerceptErelzi™Yes – S/A Yes – S/A
Nova ScotiaBiologics and BiosimilarsEtanerceptErelzi™NoYes – EDS
Prince Edward IslandBiologics and BiosimilarsEtanerceptErelzi™NoYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsEtanerceptErelzi™Yes – S/A Yes – S/A
NunavutBiologics and BiosimilarsEtanerceptErelzi™Yes- L/UYes – L/U
Northwest TerritoriesBiologics and BiosimilarsEtanerceptErelzi™Yes- L/UYes – L/U
YukonBiologics and BiosimilarsEtanerceptErelzi™NoYes – EDS
NIHBBiologics and BiosimilarsEtanerceptErelzi™NoYes- L/U
British ColumbiaBiologics and BiosimilarsEtanerceptBrenzys®Yes - S/AYes – S/A
AlbertaBiologics and BiosimilarsEtanerceptBrenzys®Yes – S/AYes – S/A
SaskatchewanBiologics and BiosimilarsEtanerceptBrenzys®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsEtanerceptBrenzys®Yes - EDSYes - EDS
OntarioBiologics and BiosimilarsEtanerceptBrenzys®Yes – L/U Yes – L/U
QuebecBiologics and BiosimilarsEtanerceptBrenzys®Yes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsEtanerceptBrenzys®Yes - S/AYes - S/A
Nova ScotiaBiologics and BiosimilarsEtanerceptBrenzys®Yes - EDSYes - EDS
Prince Edward IslandBiologics and BiosimilarsEtanerceptBrenzys®NoNo
Newfoundland and LabradorBiologics and BiosimilarsEtanerceptBrenzys®NoNo
NunavutBiologics and BiosimilarsEtanerceptBrenzys®NoNo
Northwest TerritoriesBiologics and BiosimilarsEtanerceptBrenzys®NoNo
YukonBiologics and BiosimilarsEtanerceptBrenzys®NoYes – EDS
NIHBBiologics and BiosimilarsEtanerceptBrenzys®NoNo
British ColumbiaBiologics and BiosimilarsAdalimumabHumira®No – S/A requests for psoriasis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis.  No – S/A requests for psoriatic arthritis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis.  
AlbertaBiologics and BiosimilarsAdalimumabHumira®Yes - S/A. Patients must switch to the biosimilar version by May 1, 2022.Yes - S/A. Patients must switch to the biosimilar version by May 1, 2022.
SaskatchewanBiologics and BiosimilarsAdalimumabHumira®Yes - EDS. Effective June 1, 2021, all listed Humira indications have a biosimilar adalimumab option. As such, new patients (i.e., patients without previous EDS approval for Humira) will be eligible only for a listed biosimilar formulation of adalimumab.Yes - EDS. Effective June 1, 2021, all listed Humira indications have a biosimilar adalimumab option. As such, new patients (i.e., patients without previous EDS approval for Humira) will be eligible only for a listed biosimilar formulation of adalimumab.
ManitobaBiologics and BiosimilarsAdalimumabHumira®Yes - EDS. Hadlima, Hyrimoz, Idacio, Amgevita or Idacio will be the preferred adalimumab option for all adalimumab-naïve patients prescribed an adalimumab product for psoriasis.Yes - EDS. Hadlima, Hyrimoz, Idacio, Amgevita or Idacio will be the preferred adalimumab option for all adalimumab-naïve patients prescribed an adalimumab product for psoriatic arthritis.
OntarioBiologics and BiosimilarsAdalimumabHumira®Yes - L/UNo
QuebecBiologics and BiosimilarsAdalimumabHumira®Yes - S/A. If treatment began before August 19, 2020.Yes - S/A. If treatment began before August 19, 2020.
New BrunswickBiologics and BiosimilarsAdalimumabHumira®No. All new S/A requests will be approved for biosimilar versions only. Patients on Humira must switch to the biosimilar version by November 30, 2021.No. All new S/A requests will be approved for biosimilar versions only. Patients on Humira must switch to the biosimilar version by November 30, 2021.
Nova ScotiaBiologics and BiosimilarsAdalimumabHumira®Yes- only for clients who received approval for Humira before December 15, 2021Yes- only for clients who received approval for Humira before December 15, 2021
Prince Edward IslandBiologics and BiosimilarsAdalimumabHumira®Yes - S/AYes - S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabHumira®Yes - S/A All SA requests for coverage of adalimumab for adalimumab- naïve patients will be assessed for the biosimilars of adalimumab only. Patients whose initial Special Authority was received before April 17, 2021 will be eligible for coverage of Humira.Yes - S/A All SA requests for coverage of adalimumab for adalimumab- naïve patients will be assessed for the biosimilars of adalimumab only. Patients whose initial Special Authority was received before April 17, 2021 will be eligible for coverage of Humira.
NunavutBiologics and BiosimilarsAdalimumabHumira®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabHumira®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsAdalimumabHumira®Yes - EDSYes - EDS
NIHBBiologics and BiosimilarsAdalimumabHumira®Yes- only for clients who received approval for Humira before June 11, 2021Yes- only for clients who received approval for Humira before June 11, 2021
British ColumbiaBiologics and BiosimilarsAdalimumabHadlima®Yes - S/AYes - S/A
AlbertaBiologics and BiosimilarsAdalimumabHadlima®Yes - S/AYes - S/A
SaskatchewanBiologics and BiosimilarsAdalimumabHadlima®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsAdalimumabHadlima®Yes - EDSYes - EDS
OntarioBiologics and BiosimilarsAdalimumabHadlima®Yes - L/UYes - L/U
QuebecBiologics and BiosimilarsAdalimumabHadlima®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsAdalimumabHadlima®Yes - S/AYes - S/A
Nova ScotiaBiologics and BiosimilarsAdalimumabHadlima®Yes - S/AYes - S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabHadlima®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabHadlima®Yes - S/AYes - S/A
NunavutBiologics and BiosimilarsAdalimumabHadlima®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabHadlima®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsAdalimumabHadlima®NoNo
NIHBBiologics and BiosimilarsAdalimumabHadlima®Yes - L/UYes - L/U
British ColumbiaBiologics and BiosimilarsAdalimumabHyrimoz®Yes - S/AYes - S/A
AlbertaBiologics and BiosimilarsAdalimumabHyrimoz®Yes - S/AYes - S/A
SaskatchewanBiologics and BiosimilarsAdalimumabHyrimoz®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsAdalimumabHyrimoz®Yes - EDSYes - EDS
OntarioBiologics and BiosimilarsAdalimumabHyrimoz®Yes - L/UYes - L/U
QuebecBiologics and BiosimilarsAdalimumabHyrimoz®Yes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsAdalimumabHyrimoz®Yes - S/AYes - S/A
Nova ScotiaBiologics and BiosimilarsAdalimumabHyrimoz®Yes - S/AYes - S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabHyrimoz®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabHyrimoz®Yes - S/AYes - S/A
NunavutBiologics and BiosimilarsAdalimumabHyrimoz®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabHyrimoz®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsAdalimumabHyrimoz®NoNo
NIHBBiologics and BiosimilarsAdalimumabHyrimoz®Yes - L/UYes - L/U
British ColumbiaBiologics and BiosimilarsAdalimumabIdacio®Yes - S/AYes - S/A
AlbertaBiologics and BiosimilarsAdalimumabIdacio®Yes - S/AYes - S/A
SaskatchewanBiologics and BiosimilarsAdalimumabIdacio®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsAdalimumabIdacio®Yes - EDSYes - EDS
OntarioBiologics and BiosimilarsAdalimumabIdacio®Yes - L/UYes - L/U
QuebecBiologics and BiosimilarsAdalimumabIdacio®Yes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsAdalimumabIdacio®Yes - S/AYes - S/A
Nova ScotiaBiologics and BiosimilarsAdalimumabIdacio®Yes - S/AYes - S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabIdacio®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabIdacio®Yes - S/AYes - S/A
NunavutBiologics and BiosimilarsAdalimumabIdacio®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabIdacio®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsAdalimumabIdacio®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsAdalimumabIdacio®Yes - L/UYes - L/U
British ColumbiaBiologics and BiosimilarsAdalimumabAmgevita®Yes - S/AYes - S/A
AlbertaBiologics and BiosimilarsAdalimumabAmgevita®Yes - S/AYes - S/A
SaskatchewanBiologics and BiosimilarsAdalimumabAmgevita®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsAdalimumabAmgevita®Yes - EDSYes - EDS
OntarioBiologics and BiosimilarsAdalimumabAmgevita®Yes - L/UYes - L/U
QuebecBiologics and BiosimilarsAdalimumabAmgevita®Yes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsAdalimumabAmgevita®Yes - S/AYes - S/A
Nova ScotiaBiologics and BiosimilarsAdalimumabAmgevita®Yes - S/AYes - S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabAmgevita®Yes - S/AYes - S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabAmgevita®Yes - S/AYes - S/A
NunavutBiologics and BiosimilarsAdalimumabAmgevita®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabAmgevita®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsAdalimumabAmgevita®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsAdalimumabAmgevita®Yes - L/UYes - L/U
British ColumbiaBiologics and BiosimilarsAdalimumabHulio®Yes - S/AYes - S/A
AlbertaBiologics and BiosimilarsAdalimumabHulio®Yes - S/AYes - S/A
SaskatchewanBiologics and BiosimilarsAdalimumabHulio®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsAdalimumabHulio®Yes - EDSYes - EDS
OntarioBiologics and BiosimilarsAdalimumabHulio®Yes - L/UYes - L/U
QuebecBiologics and BiosimilarsAdalimumabHulio®Yes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsAdalimumabHulio®Yes - S/AYes - S/A
Nova ScotiaBiologics and BiosimilarsAdalimumabHulio®Yes - S/AYes - S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabHulio®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabHulio®Yes - S/AYes - S/A
NunavutBiologics and BiosimilarsAdalimumabHulio®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabHulio®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsAdalimumabHulio®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsAdalimumabHulio®Yes - L/UYes - L/U
British ColumbiaBiologics and BiosimilarsAdalimumabAbriladaNoNo
AlbertaBiologics and BiosimilarsAdalimumabAbriladaYes – S/AYes – S/A
SaskatchewanBiologics and BiosimilarsAdalimumabAbriladaYes – S/AYes – S/A
ManitobaBiologics and BiosimilarsAdalimumabAbriladaYes – S/AYes – S/A
OntarioBiologics and BiosimilarsAdalimumabAbriladaYes – S/AYes – S/A
QuebecBiologics and BiosimilarsAdalimumabAbriladaYes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsAdalimumabAbriladaYes – S/AYes – S/A
Nova ScotiaBiologics and BiosimilarsAdalimumabAbriladaYes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabAbriladaNoNo
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabAbriladaYes – S/AYes – S/A
NunavutBiologics and BiosimilarsAdalimumabAbriladaYes – S/AYes – S/A
Northwest TerritoriesBiologics and BiosimilarsAdalimumabAbriladaYes – S/AYes – S/A
YukonBiologics and BiosimilarsAdalimumabAbriladaNoNo
NIHBBiologics and BiosimilarsAdalimumabAbriladaYes – S/AYes – S/A
British ColumbiaBiologics and BiosimilarsAdalimumabSimlandiNoNo
AlbertaBiologics and BiosimilarsAdalimumabSimlandiYes – S/AYes – S/A
SaskatchewanBiologics and BiosimilarsAdalimumabSimlandiYes – S/AYes – S/A
ManitobaBiologics and BiosimilarsAdalimumabSimlandiYes – S/AYes – S/A
OntarioBiologics and BiosimilarsAdalimumabSimlandiYes - L/UYes - L/U
QuebecBiologics and BiosimilarsAdalimumabSimlandiYes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsAdalimumabSimlandiYes – S/AYes – S/A
Nova ScotiaBiologics and BiosimilarsAdalimumabSimlandiYes - S/AYes - S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabSimlandiNoNo
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabSimlandiYes – S/AYes – S/A
NunavutBiologics and BiosimilarsAdalimumabSimlandiYes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabSimlandiYes - L/UYes - L/U
YukonBiologics and BiosimilarsAdalimumabSimlandiNoNo
NIHBBiologics and BiosimilarsAdalimumabSimlandiYes - L/UYes - L/U
British ColumbiaBiologics and BiosimilarsAdalimumabYuflymaNoNo
AlbertaBiologics and BiosimilarsAdalimumabYuflymaYes – S/AYes – S/A
SaskatchewanBiologics and BiosimilarsAdalimumabYuflymaYes – S/AYes – S/A
ManitobaBiologics and BiosimilarsAdalimumabYuflymaYes – S/AYes – S/A
OntarioBiologics and BiosimilarsAdalimumabYuflymaYes - L/UYes - L/U
QuebecBiologics and BiosimilarsAdalimumabYuflymaYes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsAdalimumabYuflymaNoNo
Nova ScotiaBiologics and BiosimilarsAdalimumabYuflymaNoNo
Prince Edward IslandBiologics and BiosimilarsAdalimumabYuflymaNoNo
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabYuflymaYes – S/AYes – S/A
NunavutBiologics and BiosimilarsAdalimumabYuflymaYes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabYuflymaYes - L/UYes - L/U
YukonBiologics and BiosimilarsAdalimumabYuflymaNoNo
NIHBBiologics and BiosimilarsAdalimumabYuflymaYes - L/UYes - L/U
British ColumbiaBiologics and BiosimilarsInfliximabRemicade®NoNo 
AlbertaBiologics and BiosimilarsInfliximabRemicade®NoNo 
SaskatchewanBiologics and BiosimilarsInfliximabRemicade®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsInfliximabRemicade®Yes – EDS. Inflectra, Renflexis or Avsola will be the preferred infliximab option for all infliximab-naïve patients prescribed an infliximab product.Yes – EDS. Inflectra, Renflexis or Avsola will be the preferred infliximab option for all infliximab-naïve patients prescribed an infliximab product.
OntarioBiologics and BiosimilarsInfliximabRemicade®No. May be covered through EAP in specific clinical circumstances .No. May be covered through EAP in specific clinical circumstances .
QuebecBiologics and BiosimilarsInfliximabRemicade®Yes – S/A. If treatment began before August 19, 2020 Yes – S/A. If treatment began before August 19, 2020 
New BrunswickBiologics and BiosimilarsInfliximabRemicade®No. All new S/A requests will be approved for biosimilar versions only. Patients on Remicade must switch to the biosimilar version by November 30, 2021.No. All new S/A requests will be approved for biosimilar versions only. Patients on Remicade must switch to the biosimilar version by November 30, 2021.
Nova ScotiaBiologics and BiosimilarsInfliximabRemicade®Yes – S/A. For infliximab naïve patients whose infliximab therapy is initiated after June 1, 2016, an infliximab biosimilar will be the product approved. Yes – S/A. For infliximab naïve patients whose infliximab therapy is initiated after June 1, 2016, an infliximab biosimilar will be the product approved. 
Prince Edward IslandBiologics and BiosimilarsInfliximabRemicade®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsInfliximabRemicade®Yes – S/A; Inflectra or Renflexis are the preferred infliximab therapy for treatment naïve patients (coverage will only be considered for Remicade in patients stabilized prior to June 1, 2016). No
NunavutBiologics and BiosimilarsInfliximabRemicade®NoNo
Northwest TerritoriesBiologics and BiosimilarsInfliximabRemicade®NoNo
YukonBiologics and BiosimilarsInfliximabRemicade®Yes – EDS; all new infliximab patients will be covered for Inflectra brand only.Yes – EDS; all new infliximab patients will be covered for Inflectra brand only.
NIHBBiologics and BiosimilarsInfliximabRemicade®NoNo
British ColumbiaBiologics and BiosimilarsInfliximabAvsola®Yes – S/AYes – S/A
AlbertaBiologics and BiosimilarsInfliximabAvsola®Yes – S/AYes – S/A
SaskatchewanBiologics and BiosimilarsInfliximabAvsola®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsInfliximabAvsola®Yes - EDSYes - EDS
OntarioBiologics and BiosimilarsInfliximabAvsola®Yes – L/UYes – L/U
QuebecBiologics and BiosimilarsInfliximabAvsola®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsInfliximabAvsola®Yes - S/AYes - S/A
Nova ScotiaBiologics and BiosimilarsInfliximabAvsola®NoNo
Prince Edward IslandBiologics and BiosimilarsInfliximabAvsola®NoNo
Newfoundland and LabradorBiologics and BiosimilarsInfliximabAvsola®Yes - S/AYes - SA
NunavutBiologics and BiosimilarsInfliximabAvsola®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsInfliximabAvsola®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsInfliximabAvsola®NoNo
NIHBBiologics and BiosimilarsInfliximabAvsola®Yes - L/UYes - L/U
British ColumbiaBiologics and BiosimilarsInfliximabInflectra®Yes – S/AYes – S/A
AlbertaBiologics and BiosimilarsInfliximabInflectra®Yes – S/AYes – S/A
SaskatchewanBiologics and BiosimilarsInfliximabInflectra®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsInfliximabInflectra®Yes – EDSYes – EDS
OntarioBiologics and BiosimilarsInfliximabInflectra®Yes – L/UYes – L/U
QuebecBiologics and BiosimilarsInfliximabInflectra®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsInfliximabInflectra®Yes - S/AYes - S/A
Nova ScotiaBiologics and BiosimilarsInfliximabInflectra®Yes – EDSYes – EDS
Prince Edward IslandBiologics and BiosimilarsInfliximabInflectra®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsInfliximabInflectra®Yes – S/AYes – S/A
NunavutBiologics and BiosimilarsInfliximabInflectra®Yes – L/UYes – L/U
Northwest TerritoriesBiologics and BiosimilarsInfliximabInflectra®Yes – L/UYes – L/U
YukonBiologics and BiosimilarsInfliximabInflectra®Yes - EDSYes - EDS
NIHBBiologics and BiosimilarsInfliximabInflectra®Yes - L/UYes - L/U
British ColumbiaBiologics and BiosimilarsInfliximabOmvyence™NoNo
AlbertaBiologics and BiosimilarsInfliximabOmvyence™NoNo
SaskatchewanBiologics and BiosimilarsInfliximabOmvyence™NoNo
ManitobaBiologics and BiosimilarsInfliximabOmvyence™NoNo
OntarioBiologics and BiosimilarsInfliximabOmvyence™NoNo
QuebecBiologics and BiosimilarsInfliximabOmvyence™NoNo
New BrunswickBiologics and BiosimilarsInfliximabOmvyence™NoNo
Nova ScotiaBiologics and BiosimilarsInfliximabOmvyence™NoNo
Prince Edward IslandBiologics and BiosimilarsInfliximabOmvyence™NoNo
Newfoundland and LabradorBiologics and BiosimilarsInfliximabOmvyence™NoNo
NunavutBiologics and BiosimilarsInfliximabOmvyence™NoNo
Northwest TerritoriesBiologics and BiosimilarsInfliximabOmvyence™NoNo
YukonBiologics and BiosimilarsInfliximabOmvyence™NoNo
NIHBBiologics and BiosimilarsInfliximabOmvyence™No records available on NIHB websiteNo records available on NIHB website
British ColumbiaBiologics and BiosimilarsInfliximabRemsima™NoNo
AlbertaBiologics and BiosimilarsInfliximabRemsima™NoNo
SaskatchewanBiologics and BiosimilarsInfliximabRemsima™NoNo
ManitobaBiologics and BiosimilarsInfliximabRemsima™NoNo
OntarioBiologics and BiosimilarsInfliximabRemsima™NoNo
QuebecBiologics and BiosimilarsInfliximabRemsima™NoNo
New BrunswickBiologics and BiosimilarsInfliximabRemsima™NoNo
Nova ScotiaBiologics and BiosimilarsInfliximabRemsima™NoNo
Prince Edward IslandBiologics and BiosimilarsInfliximabRemsima™NoNo
Newfoundland and LabradorBiologics and BiosimilarsInfliximabRemsima™NoNo
NunavutBiologics and BiosimilarsInfliximabRemsima™NoNo
Northwest TerritoriesBiologics and BiosimilarsInfliximabRemsima™NoNo
YukonBiologics and BiosimilarsInfliximabRemsima™NoNo
NIHBBiologics and BiosimilarsInfliximabRemsima™No records available on NIHB websiteNo records available on NIHB website
British ColumbiaBiologics and BiosimilarsInfliximabRenflexis®Yes – S/AYes – S/A
AlbertaBiologics and BiosimilarsInfliximabRenflexis®Yes – S/AYes – S/A
SaskatchewanBiologics and BiosimilarsInfliximabRenflexis®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsInfliximabRenflexis®Yes – EDSYes – EDS
OntarioBiologics and BiosimilarsInfliximabRenflexis®Yes – L/UYes – L/U
QuebecBiologics and BiosimilarsInfliximabRenflexis®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsInfliximabRenflexis®Yes - S/AYes - S/A
Nova ScotiaBiologics and BiosimilarsInfliximabRenflexis®Yes – EDSYes – EDS
Prince Edward IslandBiologics and BiosimilarsInfliximabRenflexis®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsInfliximabRenflexis®Yes – S/AYes – S/A
NunavutBiologics and BiosimilarsInfliximabRenflexis®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsInfliximabRenflexis®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsInfliximabRenflexis®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsInfliximabRenflexis®Yes - L/UYes - L/U
British ColumbiaBiologics and BiosimilarsCertolizumab pegolCimzia®Yes - L/UYes - L/U
AlbertaBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – S/A
SaskatchewanBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – EDS
ManitobaBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – EDS
OntarioBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – EAP
QuebecBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – S/A
New BrunswickBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – S/A
Nova ScotiaBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – EDS
Prince Edward IslandBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – S/A
NunavutBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – L/U
Northwest TerritoriesBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – L/U
YukonBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – EDS
NIHBBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – L/U
British ColumbiaBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/A
AlbertaBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/A
SaskatchewanBiologics and BiosimilarsGolimumabSimponi®NoYes – EDS
ManitobaBiologics and BiosimilarsGolimumabSimponi®N/AYes – EDS
OntarioBiologics and BiosimilarsGolimumabSimponi®N/ANo – EAP may cover in specific clinical circumstances. 
QuebecBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/A
New BrunswickBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/A
Nova ScotiaBiologics and BiosimilarsGolimumabSimponi®NoYes – EDS
Prince Edward IslandBiologics and BiosimilarsGolimumabSimponi®NoYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/A
NunavutBiologics and BiosimilarsGolimumabSimponi®N/AYes – L/U
Northwest TerritoriesBiologics and BiosimilarsGolimumabSimponi®N/AYes – L/U
YukonBiologics and BiosimilarsGolimumabSimponi®N/AYes – EDS
NIHBBiologics and BiosimilarsGolimumabSimponi®N/AYes – L/U
British ColumbiaBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/A
AlbertaBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/A
SaskatchewanBiologics and BiosimilarsIxekizumabTaltz®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsIxekizumabTaltz®Yes – EDSYes – EDS
OntarioBiologics and BiosimilarsIxekizumabTaltz®Yes – L/UNo 
QuebecBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/A
Nova ScotiaBiologics and BiosimilarsIxekizumabTaltz®Yes – EDSYes – EDS
Prince Edward IslandBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/A
NunavutBiologics and BiosimilarsIxekizumabTaltz®Yes – L/UYes – L/U
Northwest TerritoriesBiologics and BiosimilarsIxekizumabTaltz®Yes – L/UYes – L/U
YukonBiologics and BiosimilarsIxekizumabTaltz®NoNo
NIHBBiologics and BiosimilarsIxekizumabTaltz®Yes – L/UYes – L/U
British ColumbiaBiologics and BiosimilarsBrodalumabSiliq™NoN/A
AlbertaBiologics and BiosimilarsBrodalumabSiliq™NoN/A
SaskatchewanBiologics and BiosimilarsBrodalumabSiliq™Yes – EDSNo
ManitobaBiologics and BiosimilarsBrodalumabSiliq™Yes – EDSN/A
OntarioBiologics and BiosimilarsBrodalumabSiliq™Yes – L/UN/A
QuebecBiologics and BiosimilarsBrodalumabSiliq™Yes – S/AN/A
New BrunswickBiologics and BiosimilarsBrodalumabSiliq™Yes – S/AN/A
Nova ScotiaBiologics and BiosimilarsBrodalumabSiliq™Yes – EDSN/A
Prince Edward IslandBiologics and BiosimilarsBrodalumabSiliq™Yes – S/AN/A
Newfoundland and LabradorBiologics and BiosimilarsBrodalumabSiliq™Yes – S/AN/A
NunavutBiologics and BiosimilarsBrodalumabSiliq™Yes – L/Us.o.
Northwest TerritoriesBiologics and BiosimilarsBrodalumabSiliq™Yes – L/UN/A
YukonBiologics and BiosimilarsBrodalumabSiliq™NoN/A
NIHBBiologics and BiosimilarsBrodalumabSiliq™Yes – L/UN/A
British ColumbiaBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
AlbertaBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
SaskatchewanBiologics and BiosimilarsSecukinumabCosentyx®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsSecukinumabCosentyx®Yes – EDSYes – EDS
OntarioBiologics and BiosimilarsSecukinumabCosentyx®Yes – L/UNo 
QuebecBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
Nova ScotiaBiologics and BiosimilarsSecukinumabCosentyx®Yes – EDSYes - EDS
Prince Edward IslandBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
NunavutBiologics and BiosimilarsSecukinumabCosentyx®Yes – L/UYes – L/U
Northwest TerritoriesBiologics and BiosimilarsSecukinumabCosentyx®Yes – L/UYes – L/U
YukonBiologics and BiosimilarsSecukinumabCosentyx®Yes – EDSYes – EDS
NIHBBiologics and BiosimilarsSecukinumabCosentyx®Yes – L/UYes – L/U
British ColumbiaBiologics and BiosimilarsUstekinumabStelara®Yes – S/ANo
AlbertaBiologics and BiosimilarsUstekinumabStelara®Yes – S/ANo
SaskatchewanBiologics and BiosimilarsUstekinumabStelara®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsUstekinumabStelara®Yes – EDSNo
OntarioBiologics and BiosimilarsUstekinumabStelara®Yes – L/UNo
QuebecBiologics and BiosimilarsUstekinumabStelara®Yes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsUstekinumabStelara®Yes – S/ANo
Nova ScotiaBiologics and BiosimilarsUstekinumabStelara®Yes - EDSNo
Prince Edward IslandBiologics and BiosimilarsUstekinumabStelara®Yes – S/ANo
Newfoundland and LabradorBiologics and BiosimilarsUstekinumabStelara®Yes – S/ANo
NunavutBiologics and BiosimilarsUstekinumabStelara®Yes – L/UNo
Northwest TerritoriesBiologics and BiosimilarsUstekinumabStelara®Yes – L/UNo
YukonBiologics and BiosimilarsUstekinumabStelara®Yes – EDSNo
NIHBBiologics and BiosimilarsUstekinumabStelara®Yes – L/UNo
British ColumbiaBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/AN/A
AlbertaBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/AN/A
SaskatchewanBiologics and BiosimilarsRisankizumabSkyrizi™Yes – EDSNo
ManitobaBiologics and BiosimilarsRisankizumabSkyrizi™Yes – EDSN/A
OntarioBiologics and BiosimilarsRisankizumabSkyrizi™Yes – L/UN/A
QuebecBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/AN/A
New BrunswickBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/AN/A
Nova ScotiaBiologics and BiosimilarsRisankizumabSkyrizi™Yes – EDSN/A
Prince Edward IslandBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/A N/A
Newfoundland and LabradorBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/AN/A
NunavutBiologics and BiosimilarsRisankizumabSkyrizi™Yes – L/UN/A
Northwest TerritoriesBiologics and BiosimilarsRisankizumabSkyrizi™Yes – L/UN/A
YukonBiologics and BiosimilarsRisankizumabSkyrizi™Yes – EDSN/A
NIHBBiologics and BiosimilarsRisankizumabSkyrizi™Yes – L/UN/A
British ColumbiaBiologics and BiosimilarsGuselkumabTremfya®NoNo
AlbertaBiologics and BiosimilarsGuselkumabTremfya®NoNo
SaskatchewanBiologics and BiosimilarsGuselkumabTremfya®NoNo
ManitobaBiologics and BiosimilarsGuselkumabTremfya®NoNo
OntarioBiologics and BiosimilarsGuselkumabTremfya®NoNo
QuebecBiologics and BiosimilarsGuselkumabTremfya®NoNo
New BrunswickBiologics and BiosimilarsGuselkumabTremfya®NoNo
Nova ScotiaBiologics and BiosimilarsGuselkumabTremfya®NoNo
Prince Edward IslandBiologics and BiosimilarsGuselkumabTremfya®NoNo
Newfoundland and LabradorBiologics and BiosimilarsGuselkumabTremfya®NoNo
NunavutBiologics and BiosimilarsGuselkumabTremfya®NoNo
Northwest TerritoriesBiologics and BiosimilarsGuselkumabTremfya®NoNo
YukonBiologics and BiosimilarsGuselkumabTremfya®NoNo
NIHBBiologics and BiosimilarsGuselkumabTremfya®NoNo
British ColumbiaBiologics and BiosimilarsTildrakizumabIlumya™NoN/A
AlbertaBiologics and BiosimilarsTildrakizumabIlumya™Yes - SAN/A
SaskatchewanBiologics and BiosimilarsTildrakizumabIlumya™Yes - EDSN/A
ManitobaBiologics and BiosimilarsTildrakizumabIlumya™Yes - EDSN/A
OntarioBiologics and BiosimilarsTildrakizumabIlumya™Yes - L/UN/A
QuebecBiologics and BiosimilarsTildrakizumabIlumya™NoN/A
New BrunswickBiologics and BiosimilarsTildrakizumabIlumya™Yes - SAN/A
Nova ScotiaBiologics and BiosimilarsTildrakizumabIlumya™Yes – EDSN/A
Prince Edward IslandBiologics and BiosimilarsTildrakizumabIlumya™NoN/A
Newfoundland and LabradorBiologics and BiosimilarsTildrakizumabIlumya™Yes – SAN/A
NunavutBiologics and BiosimilarsTildrakizumabIlumya™NoN/A
Northwest TerritoriesBiologics and BiosimilarsTildrakizumabIlumya™NoN/A
YukonBiologics and BiosimilarsTildrakizumabIlumya™NoN/A
NIHBBiologics and BiosimilarsTildrakizumabIlumya™Yes – L/UN/A
British ColumbiaBiologics and BiosimilarsAbataceptOrencia®NoNo
AlbertaBiologics and BiosimilarsAbataceptOrencia®NoNo
SaskatchewanBiologics and BiosimilarsAbataceptOrencia®NoNo
ManitobaBiologics and BiosimilarsAbataceptOrencia®NoNo
OntarioBiologics and BiosimilarsAbataceptOrencia®N/ANo. EAP may cover in specific clinical circumstances. 
QuebecBiologics and BiosimilarsAbataceptOrencia®NoNo
New BrunswickBiologics and BiosimilarsAbataceptOrencia®NoNo
Nova ScotiaBiologics and BiosimilarsAbataceptOrencia®NoNo
Prince Edward IslandBiologics and BiosimilarsAbataceptOrencia®NoNo
Newfoundland and LabradorBiologics and BiosimilarsAbataceptOrencia®NoNo
NunavutBiologics and BiosimilarsAbataceptOrencia®NoNo
Northwest TerritoriesBiologics and BiosimilarsAbataceptOrencia®NoNo
YukonBiologics and BiosimilarsAbataceptOrencia®NoNo
NIHBBiologics and BiosimilarsAbataceptOrencia®NoNo
British ColumbiaSystemic DrugsMethotrexateYesYes
AlbertaSystemic DrugsMethotrexateYesYes
SaskatchewanSystemic DrugsMethotrexateYesYes
ManitobaSystemic DrugsCyclosporineYesN/A
OntarioSystemic DrugsMethotrexateYesYes
QuebecSystemic DrugsMethotrexateYesYes
New BrunswickSystemic DrugsMethotrexateYesYes
Nova ScotiaSystemic DrugsMethotrexateYesYes
Prince Edward IslandSystemic DrugsMethotrexateYesYes
Newfoundland and LabradorSystemic DrugsMethotrexateYesYes
NunavutSystemic DrugsMethotrexateYesYes
Northwest TerritoriesSystemic DrugsMethotrexateYesYes
YukonSystemic DrugsMethotrexateYesYes
NIHBSystemic DrugsMethotrexateYesYes
British ColumbiaSystemic DrugsCyclosporineYes – S/AN/A
AlbertaSystemic DrugsCyclosporineYes – S/AN/A
SaskatchewanSystemic DrugsCyclosporineYes – EDSN/A
ManitobaSystemic DrugsCyclosporineYes – EDSN/A
OntarioSystemic DrugsCyclosporineYesN/A
QuebecSystemic DrugsCyclosporineYesN/A
New BrunswickSystemic DrugsCyclosporineYesN/A
Nova ScotiaSystemic DrugsCyclosporineYesN/A
Prince Edward IslandSystemic DrugsCyclosporineYesN/A
Newfoundland and LabradorSystemic DrugsCyclosporineYesN/A
NunavutSystemic DrugsCyclosporineYesN/A
Northwest TerritoriesSystemic DrugsCyclosporineYesN/A
YukonSystemic DrugsCyclosporineYesN/A
NIHBSystemic DrugsCyclosporineCyclosporineYesN/A
British ColumbiaSystemic DrugsAcitretinSoriatane®YesN/A
AlbertaSystemic DrugsAcitretinSoriatane®YesN/A
SaskatchewanSystemic DrugsAcitretinSoriatane®Yes – EDSN/A
ManitobaSystemic DrugsAcitretinSoriatane®YesN/A
OntarioSystemic DrugsAcitretinSoriatane®YesN/A
QuebecSystemic DrugsAcitretinSoriatane®YesN/A
New BrunswickSystemic DrugsAcitretinSoriatane®YesN/A
Nova ScotiaSystemic DrugsAcitretinSoriatane®YesN/A
Prince Edward IslandSystemic DrugsAcitretinSoriatane®Yes-SAN/A
Newfoundland and LabradorSystemic DrugsAcitretinSoriatane®YesN/A
NunavutSystemic DrugsAcitretinSoriatane®YesN/A
Northwest TerritoriesSystemic DrugsAcitretinSoriatane®YesN/A
YukonSystemic DrugsAcitretinSoriatane®Yes – EDSN/A
NIHBSystemic DrugsAcitretinSoriatane®YesN/A
British ColumbiaSystemic DrugsApremilastOtezla®NoNo
AlbertaSystemic DrugsApremilastOtezla®NoNo
SaskatchewanSystemic DrugsApremilastOtezla®NoNo
ManitobaSystemic DrugsApremilastOtezla®NoNo
OntarioSystemic DrugsApremilastOtezla®NoNo
QuebecSystemic DrugsApremilastOtezla®Yes – S/ANo
New BrunswickSystemic DrugsApremilastOtezla®NoNo
Nova ScotiaSystemic DrugsApremilastOtezla®NoNo
Prince Edward IslandSystemic DrugsApremilastOtezla®NoNo
Newfoundland and LabradorSystemic DrugsApremilastOtezla®NoNo
NunavutSystemic DrugsApremilastOtezla®NoNo
Northwest TerritoriesSystemic DrugsApremilastOtezla®NoNo
YukonSystemic DrugsApremilastOtezla®NoNo
NIHBSystemic DrugsApremilastOtezla®NoNo 
British ColumbiaSystemic DrugsLeflunomideArava®NoNo 
AlbertaSystemic DrugsLeflunomideArava®NoNo
SaskatchewanSystemic DrugsLeflunomideArava®NoYes – EDS
ManitobaSystemic DrugsLeflunomideArava®NoNo
OntarioSystemic DrugsLeflunomideArava®YesYes
QuebecSystemic DrugsLeflunomideArava®N/AYes
New BrunswickSystemic DrugsLeflunomideArava®N/AYes
Nova ScotiaSystemic DrugsLeflunomideArava®N/AYes
Prince Edward IslandSystemic DrugsLeflunomideArava®N/AYes
Newfoundland and LabradorSystemic DrugsLeflunomideArava®N/AYes
NunavutSystemic DrugsLeflunomideArava®N/AYes
Northwest TerritoriesSystemic DrugsLeflunomideArava®N/AYes
YukonSystemic DrugsLeflunomideArava®NoNo
NIHBSystemic DrugsLeflunomideArava®YesYes
British ColumbiaSystemic DrugsSulfasalazineYesYes
AlbertaSystemic DrugsSulfasalazineYesYes
SaskatchewanSystemic DrugsSulfasalazineN/AYes
ManitobaSystemic DrugsSulfasalazineYesYes
OntarioSystemic DrugsSulfasalazineN/AYes
QuebecSystemic DrugsSulfasalazineN/AYes
New BrunswickSystemic DrugsSulfasalazineN/AYes
Nova ScotiaSystemic DrugsSulfasalazineN/AYes
Prince Edward IslandSystemic DrugsSulfasalazineN/AYes
Newfoundland and LabradorSystemic DrugsSulfasalazineN/AYes
NunavutSystemic DrugsSulfasalazineN/AYes
Northwest TerritoriesSystemic DrugsSulfasalazineN/AYes
YukonSystemic DrugsSulfasalazineN/ANo
NIHBSystemic DrugsSulfasalazineYesYes
British ColumbiaSystemic DrugsCelecoxibNoYes – S/A
AlbertaSystemic DrugsCelecoxibNoNo
SaskatchewanSystemic DrugsCelecoxibYesYes
ManitobaSystemic DrugsCelecoxibYesYes
OntarioSystemic DrugsCelecoxibN/ANo
QuebecSystemic DrugsCelecoxibN/AYes
New BrunswickSystemic DrugsCelecoxibN/AYes
Nova ScotiaSystemic DrugsCelecoxibN/ANo
Prince Edward IslandSystemic DrugsCelecoxibN/AYes
Newfoundland and LabradorSystemic DrugsCelecoxibN/AYes
NunavutSystemic DrugsCelecoxibN/AYes
Northwest TerritoriesSystemic DrugsCelecoxibN/AYes
YukonSystemic DrugsCelecoxibN/AYes
NIHBSystemic DrugsCelecoxibYesYes
British ColumbiaSystemic DrugsTofacitinibXeljanz®N/ANo
AlbertaSystemic DrugsTofacitinibXeljanz®N/ANo
SaskatchewanSystemic DrugsTofacitinibXeljanz®N/ANo
ManitobaSystemic DrugsTofacitinibXeljanz®N/ANo
OntarioSystemic DrugsTofacitinibXeljanz®N/ANo
QuebecSystemic DrugsTofacitinibXeljanz®N/ANo
New BrunswickSystemic DrugsTofacitinibXeljanz®N/ANo
Nova ScotiaSystemic DrugsTofacitinibXeljanz®N/ANo
Prince Edward IslandSystemic DrugsTofacitinibXeljanz®NoNo
Newfoundland and LabradorSystemic DrugsTofacitinibXeljanz®N/ANo
NunavutSystemic DrugsTofacitinibXeljanz®NoNo
Northwest TerritoriesSystemic DrugsTofacitinibXeljanz®NoNo
YukonSystemic DrugsTofacitinibXeljanz®NoNo
NIHBSystemic DrugsTofacitinibXeljanz®N/ANo
British ColumbiaPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®YesN/A
AlbertaPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®YesN/A
SaskatchewanPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®YesN/A
ManitobaPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®YesN/A
OntarioPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®Yes – L/UN/A
QuebecPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®YesN/A
New BrunswickPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®YesN/A
Nova ScotiaPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®Yes - EDSN/A
Prince Edward IslandPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®YesN/A
Newfoundland and LabradorPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®YesN/A
NunavutPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®YesN/A
Northwest TerritoriesPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®YesN/A
YukonPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®YesN/A
NIHBPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®YesN/A
British ColumbiaPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®NoN/A
AlbertaPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®NoN/A
SaskatchewanPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®NoN/A
ManitobaPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®NoN/A
OntarioPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®Yes – L/UN/A
QuebecPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®YesN/A
New BrunswickPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®YesN/A
Nova ScotiaPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®YesN/A
Prince Edward IslandPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®YesN/A
Newfoundland and LabradorPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®NoN/A
NunavutPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®YesN/A
Northwest TerritoriesPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®YesN/A
YukonPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®YesN/A
NIHBPrescription Topical TreatmentsVitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®YesN/A
British ColumbiaPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYesN/A
AlbertaPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYesN/A
SaskatchewanPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYesN/A
ManitobaPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYes – EDSN/A
OntarioPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYes – in specific clinical situationsN/A
QuebecPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYes – S/AN/A
New BrunswickPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYesN/A
Nova ScotiaPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYes – EDSN/A
Prince Edward IslandPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYesN/A
Newfoundland and LabradorPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYes – S/AN/A
NunavutPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYesN/A
Northwest TerritoriesPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYesN/A
YukonPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYesN/A
NIHBPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYesN/A
British ColumbiaPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentNoN/A
AlbertaPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYesN/A
SaskatchewanPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYesN/A
ManitobaPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentNoN/A
OntarioPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYes – in specific clinical situationsN/A
QuebecPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYes – S/AN/A
New BrunswickPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYesN/A
Nova ScotiaPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentNoN/A
Prince Edward IslandPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentNoN/A
Newfoundland and LabradorPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentNoN/A
NunavutPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYesN/A
Northwest TerritoriesPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYesN/A
YukonPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYesN/A
NIHBPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYesN/A
British ColumbiaPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamNoN/A
AlbertaPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYesN/A
SaskatchewanPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYesN/A
ManitobaPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYesN/A
OntarioPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYes – in specific clinical situationsN/A
QuebecPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYes – S/AN/A
New BrunswickPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYesN/A
Nova ScotiaPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYes – EDSN/A
Prince Edward IslandPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYesN/A
Newfoundland and LabradorPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYesN/A
NunavutPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYesN/A
Northwest TerritoriesPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYesN/A
YukonPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYesN/A
NIHBPrescription Topical TreatmentsCombination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYesN/A
British ColumbiaPrescription Topical TreatmentsTopical RetinoidsTazaroteneYesN/A
AlbertaPrescription Topical TreatmentsTopical RetinoidsTazaroteneYesN/A
SaskatchewanPrescription Topical TreatmentsTopical RetinoidsTazaroteneYesN/A
ManitobaPrescription Topical TreatmentsTopical RetinoidsTazaroteneNoN/A
OntarioPrescription Topical TreatmentsTopical RetinoidsTazaroteneNoN/A
QuebecPrescription Topical TreatmentsTopical RetinoidsTazaroteneNoN/A
New BrunswickPrescription Topical TreatmentsTopical RetinoidsTazaroteneYes – S/AN/A
Nova ScotiaPrescription Topical TreatmentsTopical RetinoidsTazaroteneYes – EDSN/A
Prince Edward IslandPrescription Topical TreatmentsTopical RetinoidsTazaroteneNoN/A
Newfoundland and LabradorPrescription Topical TreatmentsTopical RetinoidsTazaroteneYes – S/AN/A
NunavutPrescription Topical TreatmentsTopical RetinoidsTazaroteneYesN/A
Northwest TerritoriesPrescription Topical TreatmentsTopical RetinoidsTazaroteneYesN/A
YukonPrescription Topical TreatmentsTopical RetinoidsTazaroteneYesN/A
NIHBPrescription Topical TreatmentsTopical RetinoidsTazaroteneYesN/A
British ColumbiaPrescription Topical TreatmentsHalobetasol propionate and tazaroteneDUOBRII®NoN/A
AlbertaPrescription Topical TreatmentsHalobetasol propionate and tazaroteneDUOBRII®Yes - SAN/A
SaskatchewanPrescription Topical TreatmentsHalobetasol propionate and tazaroteneDUOBRII®NoN/A
ManitobaPrescription Topical TreatmentsHalobetasol propionate and tazaroteneDUOBRII®YesN/A
OntarioPrescription Topical TreatmentsHalobetasol propionate and tazaroteneDUOBRII®NoN/A
QuebecPrescription Topical TreatmentsHalobetasol propionate and tazaroteneDUOBRII®NoN/A
New BrunswickPrescription Topical TreatmentsHalobetasol propionate and tazaroteneDUOBRII®YesN/A
Nova ScotiaPrescription Topical TreatmentsHalobetasol propionate and tazaroteneDUOBRII®NoN/A
Prince Edward IslandPrescription Topical TreatmentsHalobetasol propionate and tazaroteneDUOBRII®NoN/A
Newfoundland and LabradorPrescription Topical TreatmentsHalobetasol propionate and tazaroteneDUOBRII®NoN/A
NunavutPrescription Topical TreatmentsHalobetasol propionate and tazaroteneDUOBRII®NoN/A
Northwest TerritoriesPrescription Topical TreatmentsHalobetasol propionate and tazaroteneDUOBRII®NoN/A
YukonPrescription Topical TreatmentsHalobetasol propionate and tazaroteneDUOBRII®NoN/A
NIHBPrescription Topical TreatmentsHalobetasol propionate and tazaroteneDUOBRII®YesN/A
British ColumbiaBiologics and BiosimilarsBimekizumabBimzelx®NoNo
AlbertaBiologics and BiosimilarsBimekizumabBimzelx®NoNo
SaskatchewanBiologics and BiosimilarsBimekizumabBimzelx®NoNo
ManitobaBiologics and BiosimilarsBimekizumabBimzelx®NoNo
OntarioBiologics and BiosimilarsBimekizumabBimzelx®NoNo
QuebecBiologics and BiosimilarsBimekizumabBimzelx®NoNo
New BrunswickBiologics and BiosimilarsBimekizumabBimzelx®NoNo
Nova ScotiaBiologics and BiosimilarsBimekizumabBimzelx®NoNo
Prince Edward IslandBiologics and BiosimilarsBimekizumabBimzelx®NoNo
Newfoundland and LabradorBiologics and BiosimilarsBimekizumabBimzelx®NoNo
NunavutBiologics and BiosimilarsBimekizumabBimzelx®NoNo
Northwest TerritoriesBiologics and BiosimilarsBimekizumabBimzelx®NoNo
YukonBiologics and BiosimilarsBimekizumabBimzelx®NoNo
NIHBBiologics and BiosimilarsBimekizumabBimzelx®NoNo
British ColumbiaSystemic DrugsUpadacitinibRinvoq®N/ANo
AlbertaSystemic DrugsUpadacitinibRinvoq®N/AYes – S/A
SaskatchewanSystemic DrugsUpadacitinibRinvoq®N/AYes – EDS
ManitobaSystemic DrugsUpadacitinibRinvoq®N/ANo
OntarioSystemic DrugsUpadacitinibRinvoq®N/ANo
QuebecSystemic DrugsUpadacitinibRinvoq®N/AYes – S/A 
New BrunswickSystemic DrugsUpadacitinibRinvoq®N/ANo
Nova ScotiaSystemic DrugsUpadacitinibRinvoq®N/ANo
Prince Edward IslandSystemic DrugsUpadacitinibRinvoq®N/ANo
Newfoundland and LabradorSystemic DrugsUpadacitinibRinvoq®N/ANo
NunavutSystemic DrugsUpadacitinibRinvoq®N/ANo
Northwest TerritoriesSystemic DrugsUpadacitinibRinvoq®N/ANo
YukonSystemic DrugsUpadacitinibRinvoq®N/ANo
NIHBSystemic DrugsUpadacitinibRinvoq®N/AYes- L/U

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.